BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 26960449)

  • 1. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
    Ohba S; Hirose Y
    Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of glioma and IDH1/IDH2 mutations.
    Rossetto M; Ciccarino P; Boisselier B; Labussiere M; Sanson M
    Rev Neurol (Paris); 2011 Oct; 167(10):699-703. PubMed ID: 21885076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 and IDH2 mutations in gliomas.
    Cohen AL; Holmen SL; Colman H
    Curr Neurol Neurosci Rep; 2013 May; 13(5):345. PubMed ID: 23532369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [IDH1/2 mutations in gliomas].
    Nobusawa S; Yokoo H
    Brain Nerve; 2011 Dec; 63(12):1378-86. PubMed ID: 22147457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
    Zhang C; Moore LM; Li X; Yung WK; Zhang W
    Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
    Johannessen TA; Mukherjee J; Viswanath P; Ohba S; Ronen SM; Bjerkvig R; Pieper RO
    Mol Cancer Res; 2016 Oct; 14(10):976-983. PubMed ID: 27430238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocitrate dehydrogenase 1 and 2 mutations in gliomas.
    Megova M; Drabek J; Koudelakova V; Trojanec R; Kalita O; Hajduch M
    J Neurosci Res; 2014 Dec; 92(12):1611-20. PubMed ID: 25078896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
    Weller M; Wick W; von Deimling A
    Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
    Kato Kaneko M; Ogasawara S; Kato Y
    Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathogenesis of IDH mutations in gliomas.
    Ichimura K
    Brain Tumor Pathol; 2012 Jul; 29(3):131-9. PubMed ID: 22399191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
    Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
    J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
    Kloosterhof NK; Bralten LB; Dubbink HJ; French PJ; van den Bent MJ
    Lancet Oncol; 2011 Jan; 12(1):83-91. PubMed ID: 20615753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.
    Borodovsky A; Seltzer MJ; Riggins GJ
    Curr Opin Oncol; 2012 Jan; 24(1):83-9. PubMed ID: 22080945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
    Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
    J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.
    Schaap FG; French PJ; Bovée JV
    Adv Anat Pathol; 2013 Jan; 20(1):32-8. PubMed ID: 23232569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioma-derived mutations in IDH: from mechanism to potential therapy.
    Fu Y; Huang R; Du J; Yang R; An N; Liang A
    Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
    Guo C; Pirozzi CJ; Lopez GY; Yan H
    Curr Opin Neurol; 2011 Dec; 24(6):648-52. PubMed ID: 22002076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.